Most Read Articles
Stephen Padilla, 04 Sep 2019
Use of sodium glucose cotransporter 2 (SGLT2), as compared with dipeptidyl peptidase 4 (DPP4), inhibitors appears to reduce the risk of heart failure and any-cause death without major cardiovascular events in the primary intention-to-treat analysis, according to a study.
Pearl Toh, 04 Sep 2019
More intensive LDL-lowering by adding ezetimibe to simvastatin in elderly individuals aged ≥75 years significantly reduced recurrent cardiovascular (CV) events without raising safety issues compared with simvastatin alone, a secondary analysis of the IMPROVE-IT* has shown.
27 Aug 2019
A once-weekly regimen of 25 mg trelagliptin is effective and safe for type 2 diabetes mellitus (T2DM) patients with severe renal impairment or end-stage renal disease, reports a new study.
Elvira Manzano, 2 days ago

The US Preventive Services Task Force (USPSTF), in an update of its 2013 recommendations, called on clinicians to offer risk-reducing medications to women who are at increased risk for breast cancer but at low risk for adverse effects.

Antibiotic exposure not a risk factor for coeliac disease in children

02 Jul 2019

Prenatal or postnatal antibiotic exposure does not contribute to an increased risk of developing coeliac disease (CD) in children, according to a recent study.

Researchers conducted a systematic review of studies in which either women during any trimester of pregnancy or infants and young children underwent intravenous or oral antibiotic treatment if the exposure preceded the CD diagnosis. A total of six studies were included.

All studies evaluated the exposure to any antibiotics, while specific types of antibiotics such as penicillins, cephalosporins and macrolides were considered only in three studies. One study provided specific data about early (≤17 weeks of pregnancy) and late (pregnancy week 18 until delivery) pregnancy. For postnatal exposure, the age at antibiotic exposure ranged from birth to 4 years.

In the large Norwegian and Swedish cohorts that evaluated prenatal antibiotic exposure, no association with the risk of CD was found (adjusted odds ratio [OR], 1.16, 95 percent CI, 0.94–1.43 and adjusted hazards ratio [HR], 1.33, 0.69–2.56, respectively).

On the other hand, the results were contradictory in three studies that explored the association between postnatal antibiotic exposure and the risk of CD, with only the Italian cohort study reporting a significant positive association (adjusted incidence rate ratio, 1.24, 1.07–1.43).

Finally, a large multicentre cohort study that evaluated the association between postnatal antibiotic exposure and CD autoimmunity in human leukocyte antigen (HLA)-positive subjects showed null results.

Additional investigation is still needed to elucidate the effects of antibiotic use or underlying infections, or both, on the development of CD/CD autoimmunity, the researchers said.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Stephen Padilla, 04 Sep 2019
Use of sodium glucose cotransporter 2 (SGLT2), as compared with dipeptidyl peptidase 4 (DPP4), inhibitors appears to reduce the risk of heart failure and any-cause death without major cardiovascular events in the primary intention-to-treat analysis, according to a study.
Pearl Toh, 04 Sep 2019
More intensive LDL-lowering by adding ezetimibe to simvastatin in elderly individuals aged ≥75 years significantly reduced recurrent cardiovascular (CV) events without raising safety issues compared with simvastatin alone, a secondary analysis of the IMPROVE-IT* has shown.
27 Aug 2019
A once-weekly regimen of 25 mg trelagliptin is effective and safe for type 2 diabetes mellitus (T2DM) patients with severe renal impairment or end-stage renal disease, reports a new study.
Elvira Manzano, 2 days ago

The US Preventive Services Task Force (USPSTF), in an update of its 2013 recommendations, called on clinicians to offer risk-reducing medications to women who are at increased risk for breast cancer but at low risk for adverse effects.